Compare Adaptive Biotechnologies Corp (ADPT) vs Centrus Energy Corp (LEU) Price & Performance

ADPT trades at $24.46, down 3.66% today but remains near its 52-week high. The stock shows bullish technical signals with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025, while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to a pure-play MRD diagnostics business following the Immune Medicine separation has generated positive investor sentiment, with 65% of analysts maintaining buy ratings.

Outlook remains cautiously optimistic as ADPT's MRD business demonstrates strong growth potential with 49% YoY revenue expansion. Key risks include persistent negative profitability metrics and execution challenges during the business separation. The consensus price target of $25.50 suggests modest upside potential from current levels, contingent on continued operational improvement.

Centrus Energy (LEU) trades at $185.06, down 2.18% on the day, with a bullish technical signal and key support at $183. The company reported Q2 2026 revenue of $176.1 million, beating estimates, and holds a $4.5 billion backlog, supported by a $900 million DOE award and a new HALEU supply agreement with X-energy (Seeking Alpha, August 13, 2026).

Outlook is positive due to strong government backing and nuclear fuel demand, but risks include margin compression from rising costs and execution challenges in scaling production. Analysts maintain a consensus price target of $228.50, with 42% buy ratings, indicating cautious optimism for growth driven by the nuclear renaissance.